SCHEMBL6282379

SCHEMBL6282379

CCCn1cc(C(=O)OCC)c(=O)c2ccoc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
MAOB P27338 1/20 0.45
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP1A2 P05177 1/20 0.41
HTT P42858 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 2/20 0.40
CNR1 P21554 1/20 0.40
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CLEC4M Q9H2X3 1/20 0.39
P2RX3 P56373 1/20 0.39
TSHR P16473 2/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284441 0.90 LMNA (0.56) LMNATDP1MAOBKMT2AKDM4E
SCHEMBL6278291 0.87 LMNA (0.47) LMNATDP1MAOBKMT2AKDM4E
SCHEMBL6282519 0.86 TSHR (0.48) LMNATDP1MAOBKDM4EALDH1A1
SCHEMBL6281429 0.86 MAOB (0.48) LMNATDP1MAOBKMT2AKDM4E
SCHEMBL6285810 0.78 ADRB2 (0.45) LMNATDP1MAOBKMT2AKDM4E
SCHEMBL6281174 0.78 MAOB (0.49) LMNATDP1MAOBKDM4EALDH1A1
SCHEMBL6281585 0.74 HPGD (0.47) LMNATDP1MAOBKMT2AKDM4E
SCHEMBL4141591 0.73 LMNA (0.61) LMNATDP1KMT2AKDM4EALDH1A1
SCHEMBL3003325 0.73 LMNA (0.67) LMNATDP1KMT2AKDM4EALDH1A1
SCHEMBL7120371 0.73 LMNA (0.52) LMNATDP1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6878705-B2 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents PFIZER (US) 2005-04-12 US disclosed
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY 2004-12-23 US disclosed
EP-1465895-A2 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-10-13 EP disclosed
WO-2003059911-A2 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS IL4, ZC3HAV1, IRF3 LMNA 4193/4885TDP1 1612/4885MAOB 3232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.